{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:59:20Z","timestamp":1788922760278,"version":"build-2803163510"},"reference-count":104,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/1-064-01\/503-11-001"],"award-info":[{"award-number":["503\/1-064-01\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, with incidence steadily increasing due to cumulative ultraviolet (UV) exposure, impaired immune surveillance, and chronic tissue damage. While most cases are effectively managed with surgical excision, a subset progress to locally advanced or metastatic disease, associated with high recurrence rates, limited curative options, and poor prognosis. The introduction of immune checkpoint inhibitors (ICIs) targeting the PD-1\/PD-L1 axis has significantly altered the management of advanced cSCC. Cemiplimab and pembrolizumab are now established systemic therapies, producing durable responses in a proportion of patients. These outcomes reflect the typically high tumor mutational burden and immunogenic microenvironment of cSCC. However, therapeutic decision-making remains particularly complex in several high-risk populations, including solid organ transplant recipients at risk of allograft rejection, patients with chronic dermatologic disorders or non-healing wounds that predispose to carcinogenesis, and individuals with rare hereditary syndromes such as recessive dystrophic epidermolysis bullosa. These so-called challenging populations are frequently excluded from pivotal trials, resulting in limited evidence regarding efficacy, safety, and optimal treatment strategies. This review summarizes current evidence on the management of advanced cSCC in high-risk and underserved patient groups, integrating trial data, real-world evidence, and contemporary guidelines. It also highlights key gaps in knowledge and outlines future directions, with particular focus on the interplay between host immune status, tumor biology, and therapeutic response.<\/jats:p>","DOI":"10.3390\/cancers17223681","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:05:31Z","timestamp":1763463931000},"page":"3681","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Blockade Therapy for Advanced Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients, Transplant Recipients, and Individuals with Hereditary Syndromes: A Narrative Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Marta","family":"Pabianek","sequence":"first","affiliation":[{"name":"Chemotherapy Unit and One-Day Chemotherapy Unit, Specialist Oncology Hospital NU-MED, 97-200 Tomasz\u00f3w Mazowiecki, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Lesiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of \u0141\u00f3d\u017a, 91-347 \u0141\u00f3d\u017a, Poland"},{"name":"Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of \u0141\u00f3d\u017a, 91-347 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Narbutt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of \u0141\u00f3d\u017a, 91-347 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovic","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-3383","authenticated-orcid":false,"given":"Magdalena","family":"Ciazynska","sequence":"additional","affiliation":[{"name":"Chemotherapy Unit and One-Day Chemotherapy Unit, Specialist Oncology Hospital NU-MED, 97-200 Tomasz\u00f3w Mazowiecki, Poland"},{"name":"Department of Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of \u0141\u00f3d\u017a, 91-347 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging","volume":"78","author":"Que","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ci\u0105\u017cy\u0144ska, M., Kami\u0144ska-Winciorek, G., Lange, D., Lewandowski, B., Reich, A., S\u0142awi\u0144ska, M., Pabianek, M., Szczepaniak, K., Hankiewicz, A., and U\u0142a\u0144ska, M. (2021). The incidence and clinical analysis of non-melanoma skin cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-94435-7"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ci\u0105\u017cy\u0144ska, M., Pabianek, M., S\u0142awi\u0144ska, M., Reich, A., Lewandowski, B., Szczepaniak, K., U\u0142a\u0144ska, M., Nejc, D., Brodowski, R., and Sobjanek, M. (2022). Risk Factors and Clinicopathological Features for Developing a Subsequent Primary Cutaneous Squamous and Basal Cell Carcinomas. Cancers, 14.","DOI":"10.3390\/cancers14133069"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jiang, R., Fritz, M., and Que, S.K.T. (2024). Cutaneous Squamous Cell Carcinoma: An Updated Review. Cancers, 16.","DOI":"10.3390\/cancers16101800"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hed.24580","article-title":"Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines in Oncology","volume":"39","author":"Skulsky","year":"2017","journal-title":"Head. Neck"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Stratigos, A.J., Garbe, C., Dessinioti, C., Lebbe, C., van Akkooi, A., Bataille, V., Bastholt, L., Dreno, B., Dummer, R., and Fargnoli, M.C. (2023). European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023. Eur. J. Cancer, 193.","DOI":"10.1016\/j.ejca.2023.113251"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0190-9622(81)70113-0","article-title":"Cancer of the skin in blacks. I. A review of 163 black patients with cutaneous squamous cell carcinoma","volume":"5","author":"Mora","year":"1981","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamadermatol.2021.3180","article-title":"Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement","volume":"157","author":"Massey","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zavdy, O., Coreanu, T., Bar-On, D.Y., Ritter, A., Bachar, G., Shpitzer, T., Kurman, N., Mansour, M., Ad-El, D., and Rozovski, U. (2023). Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients-A Comparison between Different Immunomodulating Conditions. Cancers, 15.","DOI":"10.3390\/cancers15061764"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/COH.0000000000000338","article-title":"Cutaneous malignancies in HIV","volume":"12","author":"Chang","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Khaddour, K., Murakami, N., Ruiz, E.S., and Silk, A.W. (2024). Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression. Cancers, 16.","DOI":"10.3390\/cancers16173083"},{"key":"ref_16","first-page":"1429","article-title":"Immunosuppressed patients are at increased risk of local recurrence, metastasis, and disease specific death from cutaneous squamous cell carcinoma","volume":"315","author":"Lopez","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/cncr.30601","article-title":"A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck","volume":"123","author":"Manyam","year":"2017","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.burns.2005.02.015","article-title":"Burn scar neoplasms: A literature review and statistical analysis","volume":"31","author":"Criswell","year":"2005","journal-title":"Burns"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/PRS.0b013e3181904d86","article-title":"Marjolin\u2019s ulcer: Modern analysis of an ancient problem","volume":"123","author":"Samimi","year":"2009","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_20","first-page":"154","article-title":"Marjolin\u2019s ulcer of the scalp after electrical burn: Case report and review of the literature","volume":"19","author":"Caviggioli","year":"2006","journal-title":"Ann. Burn. Fire Disasters"},{"key":"ref_21","first-page":"60","article-title":"A Comprehensive Review on Marjolin\u2019s Ulcers: Diagnosis and Treatment","volume":"3","author":"Pekarek","year":"2011","journal-title":"J. Am. Coll. Certif. Wound Spec."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/hed.24765","article-title":"Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets","volume":"39","author":"Ashford","year":"2017","journal-title":"Head Neck"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.12788\/cutis.0914","article-title":"Squamous Cell Carcinoma Arising in Chronic Inflammatory Dermatoses","volume":"113","author":"Kuraitis","year":"2024","journal-title":"Cutis"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Li, S., Townes, T., and Na\u2019ara, S. (2024). Current Advances and Challenges in the Management of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients. Cancers, 16.","DOI":"10.3390\/cancers16183118"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for Kidney Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Joo, V., Abdelhamid, K., Noto, A., Latifyan, S., Martina, F., Daoudlarian, D., De Micheli, R., Pruijm, M., Peters, S., and Hullin, R. (2024). Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nat. Commun., 15.","DOI":"10.1038\/s41467-024-47965-3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.19.00567","article-title":"Successful Administration of Cemiplimab to a Patient with Advanced Cutaneous Squamous Cell Carcinoma after Renal Transplantation","volume":"16","author":"Ali","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rabinowits, G., Park, S.J., Ellison, D.M., Worden, F.P., Gentry, R.W., Strasswimmer, J., Venna, S.S., Migden, M.R., Chandra, S., and Ruiz, E.S. (2021). Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.9547"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14796694.2024.2448416","article-title":"CASE (CemiplimAb-rwlc Survivorship and Epidemiology): A study in advanced basal cell carcinoma","volume":"21","author":"Park","year":"2025","journal-title":"Future Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dunlap, G.S., DiToro, D., Henderson, J., Shah, S.I., Manos, M., Severgnini, M., Weins, A., Guleria, I., Ott, P.A., and Murakami, N. (2023). Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy. Nat. Commun., 14.","DOI":"10.1038\/s41467-023-37230-4"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Esfahani, K., Al-Aubodah, T.A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N.A., Baran, D., Bhulaiga, N., Takano, T., and Cailhier, J.-F. (2019). Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat. Commun., 10.","DOI":"10.1038\/s41467-019-12628-1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor Regression and Allograft Rejection after Administration of Anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + Tacrolimus + Prednisone +\/\u2212 Ipilimumab for Kidney Transplant Recipients with Advanced Cutaneous Cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Alloghbi, A., Ninia, J., Alshare, B., Hotaling, J., Raza, S., and Sukari, A. (2021). Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report. Clin. Case Rep., 9.","DOI":"10.1002\/ccr3.5228"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Brereton, C., Bravo, A., and Hovenic, W. (2022). Metastatic Squamous Cell Carcinoma Presenting as Symptom of AIDS. J. Investig. Med. High Impact Case Rep., 10.","DOI":"10.1177\/23247096211068271"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lakhani, L., Alasfar, S., Bhalla, A., Aala, A., Rosenberg, A., Ostrander, D., Schollenberger, M.D.C., Brennan, D.C., and Lipson, E.J. (2021). Utility of serial donor-derived cell-free DNA measurements for detecting allograft rejection in a kidney transplant recipient after PD-1 checkpoint inhibitor administration. Transpl. Direct., 7.","DOI":"10.1097\/TXD.0000000000001113"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: A multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.35110","article-title":"Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: The AIDS Malignancy Consortium 095 Study","volume":"130","author":"Rajdev","year":"2024","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.19218","article-title":"Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies","volume":"37","author":"Lang","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Leiter, U., Loquai, C., Reinhardt, L., Rafei-Shamsabadi, D., Gutzmer, R., Kaehler, K., Heinzerling, L., Hassel, J.C., Glutsch, V., and Sirokay, J. (2020). Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: A retrospective multicenter DeCOG study of 84 patients. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000897"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients with HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Kim","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14737140.2018.1499468","article-title":"Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: A critical review","volume":"18","author":"Babey","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00006534-197601000-00013","article-title":"Marjolin\u2019s ulcer: An immunologically privileged tumor?","volume":"57","author":"Bostwick","year":"1976","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Miodovnik, M., Dolev, Y., Buchen, R., Brezis, M.R., Nikolaevski-Berlin, A., Finkel, I., Wolf, I., Ospovat, I., Gutfeld, O., and Leshem, Y. (2024). Squamous cell carcinoma arising in chronically damaged skin (Marjolin\u2019s Ulcer): Still an unmet need in the era of immunotherapy. Oncologist, 4.","DOI":"10.1093\/oncolo\/oyae326"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Miodovnik, M., Ospovat, I., Gutfeld, O., Finkel, I., Dolev, Y., and Leshem, Y. (2024). Ulcer-related cutaneous squamous cell carcinoma: New kid on the block. J. Clin. Oncol., 42.","DOI":"10.1200\/JCO.2024.42.16_suppl.e21559"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/CJI.0000000000000376","article-title":"Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series","volume":"44","author":"Shalhout","year":"2021","journal-title":"J. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ackerman, Z. (2025). Letter to the Editor in response to the article: \u201cSquamous cell carcinoma arising in chronically damaged skin (Marjolijn\u2019s Ulcer)\u201d. Oncologist, 30.","DOI":"10.1093\/oncolo\/oyaf160"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/archderm.1988.01670090032006","article-title":"Overload of iron in the skin of patients with varicose ulcers: Possible contributing role of iron accumulation in progression of the disease","volume":"124","author":"Ackerman","year":"1988","journal-title":"Arch Dermatol."},{"key":"ref_55","unstructured":"Ackerman, Z. (2011). Local iron overload in chronic leg ulcers. Isr. Med. Assoc. J., 13."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/iwj.13192","article-title":"An overview of the relationship between anaemia, iron, and venous leg ulcers","volume":"16","author":"Ferris","year":"2019","journal-title":"Int. Wound J."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Badran, O., Cohen, I., and Bar-Sela, G. (2024). The impact of iron on cancer-related immune functions in oncology: Molecular mechanisms and clinical evidence. Cancers, 16.","DOI":"10.3390\/cancers16244156"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ajpath.2017.03.003","article-title":"Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa","volume":"187","author":"Cianfarani","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, M., and Werner, S. (2008). Cancer as an overhealing wound: An old hypothesis revisited. Nat. Rev. Mol. Cell Biol., 9.","DOI":"10.1038\/nrm2455"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Condorelli, A.G., Dellambra, E., Logli, E., Zambruno, G., and Castiglia, D. (2019). Epidermolysis bullosa-associated squamous cell carcinoma: From pathogenesis to therapeutic perspectives. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225707"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e26837","DOI":"10.1002\/pbc.26837","article-title":"Dramatic response to nivolumab in xeroderma pigmentosum skin tumor","volume":"65","author":"Chambon","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_62","first-page":"303","article-title":"Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review","volume":"23","author":"Gambichler","year":"2025","journal-title":"J. Der Dtsch. Dermatol. Ges."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","article-title":"Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature","volume":"83","author":"Deinlein","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/bjd.18144","article-title":"Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum","volume":"181","author":"Ameri","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986\u20132006","volume":"60","author":"Fine","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Montaudi\u00e9, H., Chiaverini, C., Sbidian, E., Charlesworth, A., and Lacour, J.-P. (2016). Inherited epidermolysis bullosa and squamous cell carcinoma: A systematic review of 117 cases. Orphanet J. Rare Dis., 11.","DOI":"10.1186\/s13023-016-0489-9"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2230.2002.01130.x","article-title":"Epidermolysis bullosa and cancer","volume":"27","author":"Mallipeddi","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.14104","article-title":"Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: Best clinical practice guidelines","volume":"174","author":"Mellerio","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Robertson, S., Orrin, E., Lakhan, M., O\u2019sullivan, G., Felton, J., Robson, A., Greenblatt, D., Bernardis, C., McGrath, J., and Martinez, A. (2021). Cutaneous squamous cell carcinoma in epidermolysis bullosa: A 28-year retrospective study. Acta Derm. Venereol., 101.","DOI":"10.2340\/00015555-3875"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjd.21769","article-title":"The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: Analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry","volume":"187","author":"Harrs","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Hoste, E., Arwert, E.N., Lal, R., South, A.P., Salas-Alanis, J.C., Murrell, D.F., Donati, G., and Watt, F.M. (2015). Innate sensing of microbial products promotes wound-induced skin cancer. Nat. Commun., 6.","DOI":"10.1038\/ncomms6932"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cho, R.J., Alexandrov, L.B., Breems, N.Y.D., Atanasova, V.S., Farshchian, M., Purdom, E., Nguyen, T.N., Coarfa, C., Rajapakshe, K., and Prisco, M. (2018). APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci. Transl. Med., 10.","DOI":"10.1016\/j.jid.2017.07.734"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/jdv.15835","article-title":"Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"34","author":"Reimer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjd.12272","article-title":"Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma","volume":"169","author":"Kim","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_75","first-page":"448","article-title":"Wundheilungsst\u00f6rungen w\u00e4hrend der antitumor\u00f6sen Therapie mit Cetuximab bei schwerer generalisierter dystropher Epidermolysis bullosa","volume":"17","author":"Medek","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2020.0304","article-title":"Pembrolizumab for treatment of a patient with multiple cutaneous squamous cell carcinomas and recessive dystrophic epidermolysis bullosa","volume":"156","author":"Piccerillo","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Duong, T., Wong, D., Barrett, A., and Price, H. (2021). Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. BMJ Case Rep., 14.","DOI":"10.1136\/bcr-2020-238966"},{"key":"ref_78","first-page":"40","article-title":"Electrochemotherapy for metastatic squamous cell carcinoma in epidermolysis bullosa [abstract]","volume":"100","author":"Clapham","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1159\/000508933","article-title":"Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa","volume":"13","author":"Khaddour","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Trefzer, L., Hess, M.E., Scholten, L., Technau-Hafsi, K., Meiss, F., Boerries, M., Has, C., and Rafei-Shamsabadi, D. (2023). Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa. Acta Derm. Venereol., 103.","DOI":"10.2340\/actadv.v103.4870"},{"key":"ref_81","first-page":"295","article-title":"Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa","volume":"21","author":"Vasilev","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_82","unstructured":"Bruckner, A. (2020). Case report: A woman with rdeb and metastatic SCC managed with nivolumab. Acta Derm. Venereol., 100."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-2660(01)43004-5","article-title":"Xeroderma pigmentosum and related disorders: Defects in DNA repair and transcription","volume":"43","author":"Berneburg","year":"2001","journal-title":"Adv. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1684\/ejd.2012.1654","article-title":"Rare hereditary diseases with defects in DNA-repair","volume":"22","author":"Knoch","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Brambullo, T., Colonna, M.R., Vindigni, V., Piaserico, S., Masciopinto, G., Galeano, M., Costa, A.L., and Bassetto, F. (2022). Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated-A Systematic Review. Biomed. Res. Int., 2022.","DOI":"10.1155\/2022\/8549532"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Martens, M.C., Emmert, S., and Boeckmann, L. (2021). Xeroderma Pigmentosum: Gene Variants and Splice Variants. Genes, 12.","DOI":"10.3390\/genes12081173"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2174\/0113894501320281240822052657","article-title":"Revolutionizing Skin Cancer Treatment: The Rise of PD-1\/PDL-1 and CTLA-4 as Key Therapeutic Targets","volume":"25","author":"Sharma","year":"2024","journal-title":"Curr. Drug Targets"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Wessely, A., Steeb, T., Leiter, U., Garbe, C., Berking, C., and Heppt, M.V. (2020). Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239300"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"\u015eahin, E.A., Ta\u015fk\u0131ran, E.Z., Kiper, P.\u00d6.\u015e., Ayd\u0131n, B., and Utine, E. (2022). Recurrent squamous cell Carcinoma and a novel mutation nina patient with xeroderma pigmentosum: A case report. J. Med. Case Rep., 16.","DOI":"10.1186\/s13256-022-03524-2"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Steineck, A., Krumm, N., Sarthy, J.F., Pritchard, C.C., Chapman, T., Stacey, A.W., Vitanza, N.A., and Cole, B. (2019). Response to Pembrolizumab in a Patient with Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma. JCO Precis. Oncol., 3.","DOI":"10.1200\/PO.19.00028"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zhang, H., Zhong, A., and Chen, J. (2023). Immunecheckpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and metaanalysis. Skin Res. Technol., 29.","DOI":"10.1111\/srt.13229"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Lorini, L., Alberti, A., and Bossi, P. (2023). Advanced Cutaneous Squamous Cell Carcinoma Management in Immunotherapy Era: Achievements and New Challenges. Dermatol. Pract. Concept., 13.","DOI":"10.5826\/dpc.1304a251"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00262-017-2015-x","article-title":"Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma","volume":"66","author":"Gambichler","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Momen, S., Fassihi, H., Davies, H.R., Nikolaou, C., Degasperi, A., Stefanato, C.M., Dias, J.M.L., Dasgupta, D., Craythorne, E., and Sarkany, R. (2019). Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: Whole-genome sequencing aids treatment decision in end-stage disease. Cold Spring Harb. Mol. Case Stud., 5.","DOI":"10.1101\/mcs.a004408"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","article-title":"Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab","volume":"77","author":"Hauschild","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Fernandez, E.R., Tamura, D., Khan, S.G., Momen, S., Fassihi, H., Sarkany, R., DiGiovanna, J.J., and Kraemer, K.H. (2023). Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1282823"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Boziou, M., Dionyssiou, D., Dionyssopoulos, D., Lazaridou, E., Lallas, A., and Apalla, Z. (2023). Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?. Dermatol. Pract. Concept., 13.","DOI":"10.5826\/dpc.1303a160"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.18632\/oncotarget.27966","article-title":"Immunotherapy in Xeroderma Pigmentosum: A case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review","volume":"12","author":"Rubatto","year":"2021","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jdcr.2019.01.025","article-title":"Transient eruptive keratoacanthomas associated with nivolumab","volume":"5","author":"Antonov","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/CJI.0000000000000498","article-title":"Multiple Eruptive Keratoacanthomas Secondary to Nivolumab Immunotherapy","volume":"47","author":"Olsen","year":"2024","journal-title":"J. Immunother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.12788\/cutis.0935","article-title":"Cemiplimab-Associated Eruption of Generalized Eruptive Keratoacanthoma of Grzybowski","volume":"113","author":"Kang","year":"2024","journal-title":"Cutis"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Yurchenko, A.A., Rajabi, F., Braz-Petta, T., Fassihi, H., Lehmann, A., Nishigori, C., Wang, J., Padioleau, I., Gunbin, K., and Panunzi, L. (2023). Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients. Nat. Commun., 14.","DOI":"10.1038\/s41467-023-38311-0"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/carcin\/bgad030","article-title":"Mutational signatures and increased retrotransposon insertions in xeroderma pigmentosum variant skin tumors","volume":"44","author":"Corradi","year":"2023","journal-title":"Carcinogenesis"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Yurchenko, A.A., Fresneau, B., Borghese, B., Rajabi, F., Tata, Z., Genestie, C., Sarasin, A., and Nikolaev, S.I. (2023). Early-onset gynecological tumors in DNA repair-deficient xeroderma pigmentosum group C patients: A case series. Commun. Med., 3.","DOI":"10.1038\/s43856-023-00341-6"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3681\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:22:37Z","timestamp":1763464957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":104,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223681"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223681","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}